PhaseBio details dollars in AstraZeneca deal as it rolls out a plan for $86M-plus IPO
It turns out the $34 million Series D PhaseBio announced just days ago was a prelude to a bigger story: With its newly honed orphan …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
